What is new in uremic toxicity?

Pediatric Nephrology

Volumn 23, Issue 8, 2008, Pages 1211-1221

  Vanholder, Raymond ^a   Laecke, Steven ^a   Glorieux, Griet ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Convection; High flux dialysis; Middle molecules; Protein bound molecules; Removal by dialysis; Uremia; Uremic toxins

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ANGIOTENSIN II; GUANIDINE DERIVATIVE; INDOLE DERIVATIVE; INTERLEUKIN 18; PARA CRESOL; POLYPHOSPHATE; SULFATE;

ARTIFICIAL KIDNEY; ARTIFICIAL MEMBRANE; CARDIOVASCULAR DISEASE; CLASSIFICATION; HEMODIAFILTRATION; HEMODIALYSIS; HUMAN; KIDNEY METABOLISM; METABOLITE; MOLECULAR SIZE; MORBIDITY; MORTALITY; NEPHROTOXICITY; NONHUMAN; PATHOPHYSIOLOGY; PERITONEAL DIALYSIS; PHYSICAL CHEMISTRY; POROSITY; PRIORITY JOURNAL; PROTEIN BINDING; REVIEW; RISK ASSESSMENT; RISK FACTOR; TOXIN ANALYSIS; ULTRAFILTRATION; UREMIA;

CHILD; HUMANS; RENAL DIALYSIS; TOXINS, BIOLOGICAL; UREMIA;

EID: 46949111224     PISSN: 0931041X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00467-008-0762-9     Document Type: Review

References (64)

1. Vanholder R, De Smet R (1999) Pathophysiologic effects of uremic retention solutes. J Am Soc Nephrol 10(8):1815-1823
2. Vanholder R, Argiles A, Baurmeister U, Brunet P, Clark W, Cohen G, De Deyn PP, Deppisch R, Descamps-Latscha B, Henle T, Jörres A, Massy ZA, Rodriguez M, Stegmayr B, Stenvinkel P, Wratten ML (2001) Uremic toxicity: Present state of the art. Int J Artif Organs 24(10):695-725
3. Vanholder R, Massy Z, Argiles A, Spasovski G, Verbeke F, Lameire N; European Uremic Toxin Work Group (EUTox) (2005) Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol Dial Transplant 20(6):1048-1056
4. Van Biesen W, De Bacquer D, Verbeke F, Delanghe J, Lameire N, Vanholder R (2007) The glomerular filtration rate in an apparently healthy population and its relation with cardiovascular mortality during 10 years. Eur Heart J 28(4):478-483
5. Vanholder R, De Smet R, Glorieux G, Argiles A, Baurmeister U, Brunet P, Clark W, Cohen G, De Deyn PP, Deppisch R, Descamps-Latscha B, Henle T, Jörres A, Lemke HD, Massy ZA, Passlick-Deetjen J, Rodriguez M, Stegmayr B, Stenvinkel P, Tetta C, Wanner C, Zidek W; European Uremic Toxin Work Group (EUTox) (2003) Review on uremic toxins: Classification, concentration, and interindividual variability. Kidney Int 63(5):1934-1943
6. Ledebo I (1998) Principles and practice of hemofiltration and hemodiafiltration. Artif Organs 22(1):20-25
7. Lesaffer G, De Smet R, Lameire N, Dhondt A, Duym P, Vanholder R (2000) Intradialytic removal of protein-bound uraemic toxins: Role of solute characteristics and of dialyser membrane. Nephrol Dial Transplant 15(1):50-57
8. Eloot S, Torremans A, De Smet R, Marescau B, De Wachter D, De Deyn PP, Lameire N, Verdonck P, Vanholder R (2005) Kinetic behavior of urea is different from that of other water-soluble compounds: The case of the guanidino compounds. Kidney Int 67(4):1566-1575
9. Eloot S, Torremans A, De Smet R, Marescau B, De Deyn PP, Verdonck P, Vanholder R (2007) Complex compartmental behavior of small water-soluble uremic retention solutes: Evaluation by direct measurements in plasma and erythrocytes. Am J Kidney Dis 50(2):279-288
10. Ogilvie A, Blasius R, Schulze-Lohoff E, Sterzel RB (1996) Adenine dinucleotides: A novel class of signalling molecules. J Auton Pharmacol 16(6):325-328
11. Heidenreich S, Tepel M, Schluter H, Harrach B, Zidek W (1995) Regulation of rat mesangial cell growth by diadenosine phosphates. J Clin Invest 95(6):2862-2867
12. Jankowski J, Hagemann J, Yoon MS, van der Giet M, Stephan N, Zidek W, Schluter H, Tepel M (2001) Increased vascular growth in hemodialysis patients induced by platelet-derived diadenosine polyphosphates. Kidney Int 59(3):1134-1141
13. Jankowski V, Tolle M, Vanholder R, Schonfelder G, van der Giet M, Henning L, Schluter H, Paul M, Zidek W, Jankowski J (2005) Uridine adenosine tetraphosphate: A novel endothelium-derived vasoconstrictive factor. Nat Med 11(2):223-227
14. Jankowski V, Vanholder R, van der Giet M, Tolle M, Kardogan S, Gobom J, Furkert J, Oksche A, Krause E, Tran TN, Tepel M, Schuchardt M, Schluter H, Wiedon A, Beyermann M, Bader M, Todiras M, Zidek W, Jankowki J (2007) Mass-spectrometric identification of a novel angiotensin peptide in human plasma. Arterioscler Thromb Vasc Biol 27(2):297-302
15. Witko-Sarsat V, Friedlander M, Nguyen KT, Capeillere-Blandin C, Nguyen AT, Canteloup S, Dayer JM, Jungers P, Drueke T, Descamps-Latscha B (1998) Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol 161(5):2524-2532
16. Glorieux G, Helling R, Henle T, Brunet P, Deppisch R, Lameire N, Vanholder R (2004) In vitro evidence for immune activating effect of specific AGE structures retained in uremia. Kidney Int 66(5):1873-1880
17. Witko-Sarsat V, Friedlander M, Capeillere-Blandin C, Nguyen Khoa T, Nguyen AT, Zingraff J, Jungers P, Descamps-Latscha B (1996) Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 49(5):1304-1313
18. Valli A, Suliman ME, Meert N, Vanholder R, Lindholm B, Stenvinkel P, Watanabe M, Barany P, Alvestrand A, Anderstam B (2007) Overestimation of advanced oxidation protein products in uremic plasma due to presence of triglycerides and other endogenous factors. Clin Chim Acta 379(1-2):87-94
19. Selmeci L, Szekely M, Soos P, Seres L, Klinga N, Geiger A, Acsady G (2006) Human blood plasma advanced oxidation protein products (AOPP) correlates with fibrinogen levels. Free Radic Res 40(9):952-958
20. Chiang CK, Huang JW, Hsu SP, Ho TI, Pai MF, Peng YS, Liu SH, Hung KY, Tsai TJ (2006) Plasma interleukin-18 levels in hemodialysis patients: increased by dialysis process and association with interleukin-6 and tumor necrotic factor-alpha. Blood Purif 24(2):174-179
21. Chiang CK, Hsu SP, Pai MF, Peng YS, Ho TI, Liu SH, Hung KY, Tsai TJ (2004) Interleukin-18 is a strong predictor of hospitalization in haemodialysis patients. Nephrol Dial Transplant 19(11):2810-2815
22. Martinez AW, Recht NS, Hostetter TH, Meyer TW (2005) Removal of P-cresol sulfate by hemodialysis. J Am Soc Nephrol 16(11):3430-3436
23. De Loor H, Bammens B, Evenepoel P, De Preter V, Verbeke K (2005) Gas chromatographic-mass spectrometric analysis for measurement of p-cresol and its conjugated metabolites in uremic and normal serum. Clin Chem 51(8):1535-1538
24. Schepers E, Meert N, Glorieux G, Goeman J, Van der Eycken J, Vanholder R (2007) P-cresylsulphate, the main in vivo metabolite of p-cresol, activates leucocyte free radical production. Nephrol Dial Transplant 22(2):592-596
25. De Smet R, Van Kaer J, Van Vlem B, De Cubber A, Brunet P, Lameire N, Vanholder R (2003) Toxicity of free p-cresol: A prospective and cross-sectional analysis. Clin Chem 49(3):470-478
26. Bammens B, Evenepoel P, Keuleers H, Verbeke K, Vanrenterghem Y (2006) Free serum concentrations of the protein-bound retention solute p-cresol predict mortality in hemodialysis patients. Kidney Int 69(6):1081-1087
27. Bammens B, Evenepoel P, Verbeke K, Vanrenterghem Y (2003) Removal of middle molecules and protein-bound solutes by peritoneal dialysis and relation with uremic symptoms. Kidney Int 64(6):2238-2243
28. Dou L, Jourde-Chiche N, Faure V, Cerini C, Berland Y, Dignat-George F, Brunet P (2007) The uremic solute indoxyl sulfate induces oxidative stress in endothelial cells. J Thromb Haemost 5(6):1302-1308
29. Dou L, Bertrand E, Cerini C, Faure V, Sampol J, Vanholder R, Berland Y, Brunet P (2004) The uremic solutes p-cresol and indoxyl sulfate inhibit endothelial proliferation and wound repair. Kidney Int 65(2):442-451
30. Miyazaki T, Aoyama I, Ise M, Seo H, Niwa T (2000) An oral sorbent reduces overload of indoxyl sulphate and gene expression of TGF-beta1 in uremic rat kidneys. Nephrol Dial Transplant 15(11):1773-1781
31. Niwa T, Ise M, Miyazaki T (1994) Progression of glomerular sclerosis in experimental uremic rats by administration of indole, a precursor of indoxyl sulfate. Am J Nephrol 14(3):207-212
32. Niwa T, Miyazaki T, Hashimoto N, Hayashi H, Ise M, Uehara Y, Maeda K (1992) Suppressed serum and urine levels of indoxyl sulfate by oral sorbent in experimental uremic rats. Am J Nephrol 12(4):201-206
33. Schulman G, Agarwal R, Acharya M, Berl T, Blumenthal S, Kopyt N (2006) A multicenter, randomized, double-blind, placebo-controlled, dose-ranging study of AST-120 (Kremezin) in patients with moderate to severe CKD. Am J Kidney Dis 47(4):565-577
34. D'Hooge R, Van de Vijver G, Van Bogaert PP, Marescau B, Vanholder R, De Deyn PP (2003) Involvement of voltage- and ligand-gated Ca2+ channels in the neuroexcitatory and synergistic effects of putative uremic neurotoxins. Kidney Int 63(5):1764-1775
35. Glorieux GL, Dhondt AW, Jacobs P, Van Langeraert J, Lameire NH, De Deyn PP, Vanholder RC (2004) In vitro study of the potential role of guanidines in leukocyte functions related to atherogenesis and infection. Kidney Int 65(6):2184-2192
36. Perna AF, Ingrosso D, Satta E, Lombardi C, Galletti P, D'Aniello A, De Santo NG (2004) Plasma protein aspartyl damage is increased in hemodialysis patients: Studies on causes and consequences. J Am Soc Nephrol 15(10):2747-2754
37. Zoccali C, Bode-Boger S, Mallamaci F, Benedetto F, Tripepi G, Malatino L, Cataliotti A, Bella nuova I, Ferno I, Frolich J, Boger R (2001) Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: A prospective study. Lancet 358(9299):2113-2117
38. Kielstein JT, Impraim B, Simmel S, Bode-Boger SM, Tsikas D, Frolich JC, Hoeper MM, Haller H, Fliser D (2004) Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans. Circulation 109(2):172-177
39. Bode-Boger SM, Scalera F, Kielstein JT, Martens-Lobenhoffer J, Breithart G, Fobker M, Reinecke H (2006) Symmetrical dimethylarginine: A new combined parameter for renal function and extent of coronary artery disease. J Am Soc Nephrol 17(4):1128-1134
40. Locatelli F, Mastrangelo F, Redaelli B, Ronco C, Marcelli D, La Greca G, Orlandini G (1996) Effects of different membranes and dialysis technologies on patient treatment tolerance and nutritional parameters. The Italian Cooperative Dialysis Study Group. Kidney Int 50(4):1293-1302
41. Koda Y, Nishi S, Miyazaki S, Haginoshita S, Sakurabayashi T, Suzuki M, Sakai S, Yuasa Y, Hirasawa Y, Nishi T (1997) Switch from conventional to high-flux membrane reduces the risk of carpal tunnel syndrome and mortality of hemodialysis patients. Kidney Int 52(4):1096-1101
42. Fishbane S, Bucala R, Pereira BJ, Founds H, Vlassara H (1997) Reduction of plasma apolipoprotein-B by effective removal of circulating glycation derivatives in uremia. Kidney Int 52(6):1645-1650
43. Leypoldt JK, Cheung AK, Carroll CE, Stannard DC, Pereira BJ, Agadoa LY, Port FK (1999) Effect of dialysis membranes and middle molecule removal on chronic hemodialysis patient survival. Am J Kidney Dis 33(2):349-355
44. Woods HF, Nandakumar M (2000) Improved outcome for haemodialysis patients treated with high-flux membranes. Nephrol Dial Transplant 15[Suppl 1]:36-42
45. Port FK, Wolfe RA, Hulbert-Shearon TE, Daugirdas JT, Agodoa LY, Jones C, Orzol SM, Held PJ (2001) Mortality risk by hemodialyzer reuse practice and dialyzer membrane characteristics: Results from the usrds dialysis morbidity and mortality study. Am J Kidney Dis 37(2):276-286
46. Eknoyan G, Beck GJ, Cheung AK, Daugirdas JT, Greene T, Kusek JW, Allon M, Bailey J, Delmez JA, Depner TA, Dwyer JT, Levey AS, Levin NW, Milford E, Ornt DB, Rocco MV, Schulman G, Schwab SJ, Teehan BP, Toto R (2002) Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 347(25):2010-2019
47. Cheung AK, Levin NW, Greene T, Agodoa L, Bailey J, Beck G, Clark W, Levey AS, Leypoldt JK, Ornt DB, Rocco MV, Schulman G, Schwab S, Teehan B, Eknoyan G (2003) Effects of high-flux hemodialysis on clinical outcomes: Results of the HEMO study. J Am Soc Nephrol 14(12):3251-3263
48. Delmez JA, Yan G, Bailey J, Beck GJ, Beddhu S, Cheung AK, Kaysen GA, Levey AS, Sarnak MJ, Schwab SJ (2006) Cerebrovascular disease in maintenance hemodialysis patients: Results of the HEMO Study. Am J Kidney Dis 47(1):131-138
49. Cheung AK, Rocco MV, Yan G, Leypoldt JK, Levin NW, Greene TM, Agodoa L, Bailey J, Beck GJ, Clark W, Levey AS, Ornt DB, Schulman G, Schwab S, Teehan B, Eknoyan G (2006) Serum beta-2 microglobulin levels predict mortality in dialysis patients: Results of the HEMO study. J Am Soc Nephrol 17(2):546-555
50. Chauveau P, Nguyen H, Combe C, Chene G, Azar R, Cano N, Canaud B, Fouque D, Laville M, Leverve X, Roth H, Aparicio M (2005) Dialyzer membrane permeability and survival in hemodialysis patients. Am J Kidney Dis 45(3):565-571
51. Krane V, Krieter DH, Olschewski M, Marz W, Mann JF, Ritz E, Wanner C (2007) Dialyzer membrane characteristics and outcome of patients with type 2 diabetes on maintenance hemodialysis. Am J Kidney Dis 49(2):267-275
52. Locatelli F, Hannedouche T, Jacobson S, La Greca G, Loureiro A, Martin-Malo A, Papadimitriou M, Vanholder R (1999) The effect of membrane permeability on ESRD: Design of a prospective randomized multicentre trial. J Nephrol 12(2):85-88
53. Tattersall J, Martin-Malo A, Pedrini L, Basci A, Canaud B, Fouque D, Haage P, Konner K, Kooman J, Pizzarelli F, Tordoir J, Vennegoor M, Wanner C, ter Wee P, Vanholder R (2007) EBPG guideline on dialysis strategies. Nephrol Dial Transplant 22[Suppl 2]:iI5-ii21
54. Lornoy W, Becaus I, Billiouw JM, Sierens L, Van Malderen P (1998) Remarkable removal of beta-2-microglobulin by on-line hemodiafiltration. Am J Nephrol 18(2):105-108
55. Raj DS, Ouwendyk M, Francoeur R, Pierratos A (2000) beta(2)-microglobulin kinetics in nocturnal haemodialysis. Nephrol Dial Transplant 15(1):58-64
56. Ward RA, Schmidt B, Hullin J, Hillebrand GF, Samtleben W (2000) A comparison of on-line hemodiafiltration and high-flux hemodialysis: A prospective clinical study. J Am Soc Nephrol 11(12):2344-2350
57. Locatelli F, Marcelli D, Conte F, Lunido A, Malberti F, Spotti D (1999) Comparison of mortality in ESRD patients on convective and diffusive extracorporeal treatments. The Registro Lombardo Dialisi E Trapianto. Kidney Int 55(1):286-293
58. Beerenhout CH, Luik AJ, Jeuken-Mertens SG, Bekers O, Menheere P, Hover L, Klaassen S, van der Sande FM, Chericx EC, Meert N, Leunissen KM, Kooman JP (2005) Pre-dilution on-line haemofiltration vs low-flux haemodialysis: A randomized prospective study. Nephrol Dial Transplant 20(6):1155-1163
59. Canaud B, Bragg-Gresham JL, Marshall MR, Desmeules S, Gillespie BW, Depner T, Klassen P, Port FK (2006) Mortality risk for patients receiving hemodiafiltration versus hemodialysis: European results from the DOPPS. Kidney Int 69(11):2087-2093
60. Bosch JP, Lew SQ, Barlee V, Mishkin GJ, von Albertini B (2006) Clinical use of high-efficiency hemodialysis treatments: Long-term assessment. Hemodial Int 10(1):73-81
61. Penne EL, Blankestijn PJ, Bots ML, van den Dorpel MA, Grooteman MP, Nube MJ, van der Tweel I, ter Wee PM (2005) Effect of increased convective clearance by on-line hemodiafiltration on all cause and cardiovascular mortality in chronic hemodialysis patients - the Dutch CONvective TRAnsport STudy (CONTRAST): Rationale and design of a randomized controlled trial [ISRCTN38365125]. Curr Control Trials Cardiovasc Med 6(1):8
62. Meert N, Schepers E, De Smet R, Argiles A, Cohen G, Deppisch R, Drueke T, Massy Z, Spasovski G, Stegmayr B, Zidek W, Jankowski J, Vanholder R (2007) Inconsistency of reported uremic toxin concentrations. Artif Organs 31(8):600-611
63. Vanholder R, Meert N, Schepers E, Glorieux G, Argiles A, Brunet P, Cohen G, Drueke T, Mishak H, Spasovski G, Massy Z, Jankowski J (2007) Review on uraemic solutes II Variability in reported concentrations: Causes and consequences. Nephrol Dial Transplant 22(11):3115-3121
64. Montini G, Pisanello L, Testa S, Dacco V, Dello Strogolo L, Taioli E, Zacchello G, Aviolo L, Ciofani A, Claris-Appiani A, Ardissino G (2003) Urea percentiles in children with chronic renal failure. Data from the ItalKid project. Pediatr Nephrol 18(3):261-265